UK markets close in 8 hours 29 minutes
  • FTSE 100

    7,168.68
    0.00 (0.00%)
     
  • FTSE 250

    22,912.73
    0.00 (0.00%)
     
  • AIM

    1,196.05
    0.00 (0.00%)
     
  • GBP/EUR

    1.1740
    +0.0015 (+0.13%)
     
  • GBP/USD

    1.3284
    +0.0007 (+0.05%)
     
  • BTC-GBP

    42,812.37
    -397.19 (-0.92%)
     
  • CMC Crypto 200

    1,446.47
    -22.61 (-1.54%)
     
  • S&P 500

    4,513.04
    -53.96 (-1.18%)
     
  • DOW

    34,022.04
    -461.68 (-1.34%)
     
  • CRUDE OIL

    66.74
    +1.17 (+1.78%)
     
  • GOLD FUTURES

    1,775.90
    -8.40 (-0.47%)
     
  • NIKKEI 225

    27,753.37
    -182.25 (-0.65%)
     
  • HANG SENG

    23,746.03
    +87.11 (+0.37%)
     
  • DAX

    15,472.67
    +372.54 (+2.47%)
     
  • CAC 40

    6,881.87
    +160.71 (+2.39%)
     

Aerie Pharmaceuticals Announces Presentation at the 39th Annual Scientific Meeting of the American Society of Retina Specialists

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

DURHAM, N.C., October 06, 2021--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that topline results from the AR-1105 (dexamethasone intravitreal implant) Phase 2 clinical trial in patients with macular edema due to retinal vein occlusion will be presented at the 39th Annual Scientific Meeting of the American Society of Retina Specialists in San Antonio, Texas.

The presentation entitled "Phase 2 Study of Two Formulations of AR-1105 in Macular Edema (ME) Secondary to Retinal Vein Occlusion (RVO)," will be presented on Tuesday, October 12, 2021 at 10:22 a.m. Central Time by Michael A. Singer, M.D., Clinical Professor of Ophthalmology at the University of Texas Health Science Center.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for the treatment of dry eye disease, wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005028/en/

Contacts

Ami Bavishi; 908-947-3949; abavishi@aeriepharma.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting